Getty Images
Glioblastoma is the most common and also most lethal form of primary brain cancer, but the standard of care hasn’t changed in nearly two decades. Typical prognoses are just 15-17 months from diagnosis, and the five-year prognosis is just 5%. A recent BioPharma article covered a new brain cancer vaccine in Phase 3 trials that aims to extend those numbers.. Northwest Biotherapeutics’ DCVax-L vaccine has shown to extend survival in newly-diagnosed glioblastoma brain cancer patients for several months, which reached the primary and secondary endpoints of the trial.
